Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Parkinson Disease Clinical Trial

Official title: Randomized, Double-Blind, Cross-Over Study Comparing the Efficacy of Immediate and Extended-Release Melatonin as a Supplement Affecting the Sleep Cycle in Patients With Parkinson Disease and Rapid Eye Movement Sleep Behavior Disorder

Status Terminated

Clinical Trial Summary

The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Movement Sleep Behavior Disorder.

Clinical Trial Description

Enrolled patients with Parkinson disease and previously diagnosed rapid eye movement sleep behavior disorder, who are being treated at Mayo Clinic in Florida, will be randomized to receive either immediate-release melatonin or extended-release melatonin and then will be crossed over to receive the opposite intervention. The study will consist of two treatment periods of 4 weeks separated by a washout period of 2 weeks. ;

Related Conditions & MeSH terms

• Mental Disorders
• Parkinson Disease
• Rapid Eye Movement Sleep Behavior Disorder
• REM Sleep Behavior Disorder

• NCT number: NCT05307770
• Study type: Interventional
• Source: Mayo Clinic
• Status: Terminated
• Phase: N/A
• Start date: May 1, 2022
• Completion date: February 1, 2024